Aringer M, Graninger W B
Division of Rheumatology, Department of Internal Medicine III, University Vienna.
Acta Med Austriaca. 2002;29(1):33-5. doi: 10.1046/j.1563-2571.2002.01042.x.
Rheumatoid arthritis (RA) is a serious illness that can only be controlled by the appropriate use of disease modifying anti-rheumatic drugs (DMARDs). In spite of the successful use of such substances, and of methotrexate in particular, a large number of patients still experience disease progression. Leflunomide and the two anti-TNF agents, infliximab and etanercept, were therefore warmly greeted as very welcome additions to the rheumatologist's armamentarium. These successful newcomers, their strengths and problems are the focus of the present review.
类风湿性关节炎（RA）是一种严重疾病，只能通过合理使用改善病情抗风湿药（DMARDs）来控制。尽管此类药物，尤其是甲氨蝶呤已成功应用，但仍有大量患者病情进展。因此，来氟米特以及两种抗TNF药物英夫利昔单抗和依那西普作为风湿病医生武器库中非常受欢迎的新成员而备受欢迎。这些成功的新药、它们的优势和问题是本综述的重点。
